NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS). These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in the fourth qua…
